Tharimmune (THAR) Registration Filing summary

Company overview and business model

• Operates as a publicly traded company advancing institutional blockchain adoption via Canton Coin and the Canton Network, while also maintaining clinical-stage biotech R&D in immunology and inflammation.

• Implements a digital asset treasury strategy centered on acquiring and utilizing Canton Coin, including plans to act as a Super Validator and develop applications on the Canton Network.

• Maintains a pipeline of therapeutic candidates targeting immunology, inflammation, and immuno-oncology, including licensed assets and proprietary biologics.

Financial performance and metrics

• Closed a PIPE transaction in November 2025, raising approximately $545 million in gross proceeds before fees and expenses.

• Allocated $6 million from the PIPE proceeds for ongoing business operations and management compensation, with the remainder for transaction expenses and digital asset acquisition.

• Entered an ATM program for up to $64.9 million in common stock sales, with commissions up to 3% and additional advisory fees.

Use of proceeds and capital allocation

• Proceeds from offerings will be used for general corporate purposes, digital asset treasury strategy, product development, R&D, administrative expenses, and potential acquisitions.

• Management retains broad discretion over capital allocation, with investments in short-term, investment-grade instruments pending use.